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Abstract
Background: While research in the area of e-mental health has received considerable attention over the last decade, there are
still many areas that have not been addressed. One such area is the comorbidity of psychological disorders in a Web-based sample
using online assessment and diagnostic tools, and the relationships between comorbidities and psychosocial variables.
Objective: We aimed to identify comorbidities of psychological disorders of an online sample using an online diagnostic tool.
Based on diagnoses made by an automated online assessment and diagnostic system administered to a large group of online
participants, multiple comorbidities (co-occurrences) of 21 psychological disorders for males and females were identified. We
examined the relationships between dyadic comorbidities of anxiety and depressive disorders and the psychosocial variables sex,
age, suicidal ideation, social support, and quality of life.
Methods: An online complex algorithm based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition, Text Revision, was used to assign primary and secondary diagnoses of 21 psychological disorders to 12,665 online
participants. The frequency of co-occurrences of psychological disorders for males and females were calculated for all disorders.
A series of hierarchical loglinear analyses were performed to examine the relationships between the dyadic comorbidities of
depression and various anxiety disorders and the variables suicidal ideation, social support, quality of life, sex, and age.
Results: A 21-by-21 frequency of co-occurrences of psychological disorders matrix revealed the presence of multiple significant
dyadic comorbidities for males and females. Also, for those with some of the dyadic depression and the anxiety disorders, the
odds for having suicidal ideation, reporting inadequate social support, and poorer quality of life increased for those with two-disorder
comorbidity than for those with only one of the same two disorders.
Conclusions: Comorbidities of several psychological disorders using an online assessment tool within a Web-based population
were similar to those found in face-to-face clinics using traditional assessment tools. Results provided support for the transdiagnostic
approaches and confirmed the positive relationship between comorbidity and suicidal ideation, the negative relationship between
comorbidity and social support, and the negative relationship comorbidity and quality of life.
Trial Registration: Australian and New Zealand Clinical Trials Registry ACTRN121611000704998;
http://www.anzctr.org.au/trial_view.aspx?ID=336143 (Archived by WebCite at http://www.webcitation.org/618r3wvOG)
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Introduction
The comorbidity of psychological disorders is a common
problem that has serious implications for the delivery of health
care. The lifetime prevalence of any disorder has been reported
to be 46.4%, while the lifetime prevalence of 2 and 3 disorders
were found to be 27.7% and 17.3%, respectively [1]. The
12-month prevalence of any disorder was found to be 26.2%,
while the 12-month prevalence of 2 and more disorders were
reported to be 5.8% and 6%, respectively, and over the same
period, more than 40% of those with one diagnosis met the
criteria for a second diagnosis [2].
Studies on comorbidity have found strong relationships between
comorbidity and higher rates of suicide [3,4], suicidal ideation
[5], greater symptom severity [2,5], and poorer quality of life
and social support [5]. Patients diagnosed with multiple
disorders also tend to have a poorer prognosis, are less
responsive to intervention, and generally exert a greater demand
on the health care sector [3,4,6].
Two approaches have been used to investigate comorbidity.
The co-occurrence, or frequency approach, identifies individuals
with a particular diagnosis and then counts how many of them
meet the diagnostic criteria of another diagnosis. The resulting
comorbidity proportions therefore depend on the reference
group. For example, the proportion of people diagnosed with
an anxiety disorder who also meet the diagnostic criteria for an
eating disorder will be different than the proportion of people
diagnosed with an eating disorder who also meet the criteria for
that same anxiety disorder. Moreover, because there are more
people diagnosed with anxiety disorders than people diagnosed
with eating disorders, it is easier to have larger samples, and
hence more accuracy, when the reference group is
anxiety-disordered rather than eating-disordered. The second
approach identifies the psychological disorders of a group of
individuals, based on discrete or dimensional scales, and then
uses factor analysis to identify clusters of disorders, hence the
underlying structure or dimensions of comorbidity is addressed.
While comorbidity, and the structure of comorbidity using
in-clinic samples, has been the focus of many investigations for
several decades, investigating comorbidity using an online
sample is relatively new. We are not aware of any study on
comorbidity using individuals who received diagnoses based
on online diagnostic tools. The e-PASS data of the Mental
Health Online Platform (formerly Anxiety Online) (Figure 1)
[7] provide us with a unique opportunity to investigate many
facets of online therapy and assessment. We have recently
reported on the structure of comorbidity of 21 psychological
disorders, using online diagnostic assessment, based on severity
dimensional scales [5]. In this paper, we present the frequencies
of co-occurrences of 21 psychological disorders using an online
assessment tool within a Web-based sample and relate the
identified anxiety-depression clusters to suicidal ideation, social
support, and quality of life.
The comorbidities of anxiety disorders with one another are
common and have long been documented, and for some anxiety
diagnoses, the lack of discriminant validly was criticized
[5,8-13]. The presence of anxiety disorders in clinically
depressed patients is most common [14] with at least 50% of
all patients diagnosed with depression meeting the diagnostic
criteria for at least one anxiety disorder [15-17] and 46% of
those diagnosed with major depressive disorder (MDD) showing
high levels of anxiety symptoms [18]. Estimates of anxiety
disorders and MDD vary based on the age of and the target
population under study. For example, the comorbidity of anxiety
disorders and MDD in samples of children and adolescents
ranges from 15.9% to 61.9% [19,20] and 14.5% to 57% in
specific populations of adult samples [21,22]. Almeida-Filho
et al [23] found 74% of the depressed sample reported symptoms
of anxiety disorders and 61% of those with anxiety disorders
were depressed. Feva et al [24] found 50.6% of those diagnosed
with MDD met the criteria for one or more anxiety disorders.
Zimmerman et al [15] found 57.4% of 373 MDD outpatients
meeting the criteria for at least one of the anxiety disorders.
This finding was confirmed later by a meta-analysis study that
concluded that 50% of individuals with MDD met the criteria
for one or more anxiety disorders [25]. More specifically, Fava
et al [18] found that 46% of MDD patients were significantly
more likely to report symptoms associated with generalized
anxiety disorder (GAD), obsessive-compulsive disorder (OCD),
posttraumatic stress disorder (PTSD), agoraphobia without panic
disorder (AwoPD), and panic disorder with or without
agoraphobia (PD/A) than individuals without comorbid anxiety.
In addition, 57% of the depressed outpatients with an anxiety
disorder met the criteria for more than one anxiety disorder. In
their sample, the most common comorbid anxiety disorders
were social anxiety disorder (SAD) (33%), specific phobia (SP)
(13.7%), PTSD (13.4%), GAD (15%), and PD/A (14.2%) [15].
Furthermore, symptoms of insomnia and hypersomnia have also
been consistently present with anxiety disorders and MDD
[26-30].
Although research on the comorbidity of eating disorders with
other psychological disorders has produced mixed and
inconsistent results, there is sufficient empirical evidence
supporting the co-occurrence of eating disorders with other
disorders like anxiety disorders [31,32], MDD [31,33,34], body
dysmorphic disorder (BDD) [35], and substance use (drugs and
alcohol) [36,37]. The estimates of these comorbidities are
generally moderate to high with a wide range. For example,
55%-98% of those diagnosed with anorexia nervosa meet the
diagnostic criteria for another Axis I disorder [38,39].
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MDD has been found to be prevalent in individuals diagnosed
with eating disorders. Estimates of the lifetime prevalence of
MDD range from 50%-71% in anorexia nervosa and 50%-65%
in bulimia nervosa [33,40,41]. A more recent study by Jordan
et al [34] reported 63% and 51% lifetime prevalence of major
depression in a 56-female anorexia nervosa sample and a
132-female bulimia nervosa sample, aged 17-40 years,
respectively. On the higher end, Blinder et al [38] reported that
for a female sample aged 11-68 years, 92% of the 956 patients
diagnosed with anorexia nervosa and 92% of the 882 patients
diagnosed with bulimia nervosa had unipolar depression
disorder, while Salbach-Andrae et al [42] reported that 60% of
their adolescent girls aged 12-18 years exhibited comorbid mood
disorder. Conversely, among women with MDD, the lifetime
prevalence rate of anorexia nervosa was estimated at 1-7% and
of bulimia nervosa at 9-21% [43,44].
Anxiety disorders are also prevalent in individuals diagnosed
with eating disorders, although studies on anxiety disorders and
eating disorders have produced mixed results [32,45,46]. Studies
that used controlled groups reported significant comorbidities
between anxiety disorders and eating disorders [32,47-50].
Depending on which one of the anxiety disorders is under
investigation, estimates of the lifetime prevalence of anxiety
disorders in eating disorders range from as low as 0% for
specific phobia in anorexia nervosa [51] to as high as 79% for
OCD in anorexia nervosa [52], and from as low as 2% for
agoraphobia without panic disorder in bulimia nervosa [53] to
as high as 59% for SAD in bulimia nervosa [54]. A summary
of life prevalence rates of MDD and various anxiety disorders
in anorexia nervosa and bulimia nervosa is shown in Table 1
[33,34,38,47,51-59].
Table 1. Comorbidity of various anxiety disorders with anorexic nervosa and bulimia nervosa.
Highest, % [reference #]Lowest, % [reference #]Anxiety disorders/MDD
Anorexia nervosa
79% [52]14% [51]OCD
55% [54]38% [47]SAD
27% [47]3% [54]Agoraphobia without panic disorder
45% [54]0% [51]Simple/Specific Phobia
49% [47]24% [54]GAD
43% [51]13% [47]PD/A
7% [47]2% [47]PTSD
74% [33]
92% [38]
46% [33]
63% [34]
MDD
Bulimia nervosa
43% [55]4% [53]OCD
59% [54]30% [53]SAD
35% [56]2% [53]Agoraphobia without panic disorder
46% [57]3% [51]Simple/Specific Phobia
55% [58]2% [53]GAD
53% [51]10% [53]PD/A
37% [59]5% [47]PTSD
74% [33]
92% [38]
46% [33]
63% [34]
MDD
It should be noted that the time of onset for anxiety disorders,
MDD, and eating disorders are not the same. Some anxiety
disorders are associated with early childhood onset while others
are associated with onset during adolescence. However, Pallister
and Waller [46] concluded that while the relative time of onset
was inconsistent, females with eating disorders exhibited higher
rates of anxiety disorders compared to controls, and suggested
that eating disorders and anxiety disorders might have some
common underlying factors.
Another disorder that seems to be present in eating disorders,
particularly in anorexia nervosa, is BDD [35,60], coupled with
features of OCD engaging in ritualistic-like behaviors to reduce
anxiety generated by thoughts of one’s poor self-image
[35,61,62].
Finally, the substance use by individuals with psychological
disorders has long been investigated [36,63,64]. The rates of
substance use disorders in patients diagnosed with mood
disorders and anxiety disorders were reported to be 42% and
27%, respectively [37].
In summary, the comorbidities of anxiety disorders, MDD,
eating disorders, and substance use have long been established
in clinical samples using traditional face-to-face assessment and
diagnosis. Comorbidity estimates vary depending on the
psychological disorder, age of the sample, and the specific
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population sample. There are no data available on the
comorbidity of psychological disorders using online assessment
and diagnostic tools with online samples.
The first purpose of this study is to report on the co-occurrences
of 21 psychological disorders diagnosed in an online sample
using an online assessment and diagnostic tool, e-PASS. While
we will present the entire matrix of co-occurrences, we will
focus on the comorbidities of anxiety disorders, major depressive
episode (MDE), eating disorders, BDD, insomnia, hypersomnia,
and alcohol use disorder. We will also report these comorbidities
for males, females, separately, and together. The second purpose
of this study is to examine the relationships between the
identified anxiety-depression comorbidity clusters and three
variables: suicidal ideation, social support, and quality of life.
Figure 1. Anxiety Online homepage image.
Methods
Procedure
The Mental Health Online platform consists of four centers,
one of which is the assessment center containing the e-PASS
(electronic psychological assessment screening system). The
e-PASS includes a variety of demographic and personal
questions and the Kessler-6 and Suicidal Warnings measure, as
well as the online diagnostic program. Individuals can access
the Mental Health Online service from anywhere in the world
provided they have an Internet connection. People can complete
e-PASS if they are interested in the psychological assessment
function and/or if they are interested in online treatment. Those
who undertook the e-PASS were first required to register and
consent to the Mental Health Online terms and conditions [7].
The procedures for collection and reporting of the Mental Health
Online data were approved by the Swinburne University Human
Research Ethics Committee.
Diagnostic Assessment
Based on an individual’s response to some of the e-PASS
questions, a person may be given a primary diagnosis and/or
multiple secondary diagnoses. Primary or secondary diagnosis
is determined by the reported presence of Diagnostic and
Statistical Manual of Mental Disorders (4th edition, Text
Revision) (DSM-IV-TR) symptoms and the average score on
severity scales, each of which assesses the level of distress and
interference caused by the symptoms of a particular disorder.
A total of 21 clinical disorders are assessed by the e-PASS (see
[5,65] for more details). The 21 psychological disorders and
their abbreviations are shown in Multimedia Appendix 1.
The disorder specific severity score is the average of the scores
on six questions that assess how distressed one is and how much
the symptoms of a given disorder interfere in one’s life (using
a scale 0=no interference/distress to 8=severe
interference/distress). A person who does not endorse enough
of the initial DSM-IV-TR symptom criteria questions for a
particular disorder is not presented with the questions assessing
their level of distress and interference of those symptoms and
is assigned a severity score of zero. Those who endorse the
DSM-IV symptom criteria questions for a particular disorder
are presented with the six distress and interference questions
allowing the calculation of an averaged severity score ranging
from 0-8. An averaged distress and interference severity score
of 3.5 or above is considered sufficient to warrant a clinical
diagnosis. Those whose average distress and interference
severity scores are less than 3.5 are considered to warrant a
subclinical (or subthreshold) diagnosis.
The e-PASS diagnostic system was informed by the Anxiety
Disorders Interview Schedule (ADIS) clinician rating scale (a
Likert scale from 0=no symptoms, to 4=mild presence of the
disorder, to 8=very severe presence of the disorder). Most “total
scores” would not be a whole number because the system used
six rating scales and then averaged them. Thus, 4 is the typical
score by a clinician using the ADIS that indicates the “presence”
of a disorder. However, considering the decimal places resulting
from the e-PASS averaging of the six rating scales, those scoring
3.5 and above were deemed clinical.
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The psychometric properties of the e-PASS measures were
shown to have high test-retest reliability and reasonable
convergent validity with the structured clinical interviews
(Nguyen, unpublished PhD thesis 2013). However, the small
sample size and some disagreement with the structured clinical
interviews in terms of the severity levels required for a clinical
diagnosis, suggest that further validation studies with large
sample sizes are needed.
For the purpose of this work, we will construct a frequency
matrix representing the co-occurrences of all 21 psychological
disorders diagnosed by the e-PASS system. We will identify
the number of participants who met the criteria for a primary
disorder (reference group) and then establish the proportion of
the reference group who were given a secondary diagnosis for
each of the remaining 21 disorders. We will also calculate these
frequencies for males and females.
Participants
A total of 13,414 individuals completed the e-PASS phase
between October 2009 and October 2012 and received at least
one clinical diagnosis. The sample consisted of 3974 (29.6%)
males whose ages ranged between 18-85 years old with a mean
of 36.88 (SD 12.59) years, and 9440 (70.4%) females whose
ages ranged between 18-86 years old with a mean of 33.66 (SD
11.57) years. A total of 749 individuals received a clinical
diagnosis (severity score greater than 3.5) of only one disorder,
leaving 12,665 individuals who were classified as having a
clinical or subclinical diagnosis for two or more of the 21
disorders assessed by e-PASS.
Analysis
The frequency of male and female participants who received a
primary diagnosis on any particular disorder was first identified.
Then, for each group, the frequencies of receiving secondary
diagnoses for all 21 disorders were calculated. A series of
hierarchical loglinear regression procedures were used to
examine the relationships between anxiety-depression disorders
and suicidal ideation, social support, and quality of life. For the
significant comorbidity relationships with suicidal ideation,
social support, and quality of life, demographic variables will
also be explored.
Results
Overview
A frequency matrix of 21-by-21 disorders is shown in
Multimedia Appendix 2. The number of cases of males and
females receiving a primary disorder is shown in column 3 for
each disorder shown column 1. Columns 4 and onward in
Multimedia Appendix 2 show the number of males, females,
and total and their associated percentages of those receiving
secondary diagnoses. For example, of the 858 males, 1761
females, and 2649 overall who received a primary diagnosis of
MDE, there were 207 (24.13%) males, 505 (28.68%) females,
and 712 (26.88%) overall who received a secondary diagnosis
of PD/A, respectively. Conversely, of the 478 males, 1000
females, and 1478 overall who received a primary diagnosis of
PD/A, there were 289 (60.46%) males, 615 (61.50%) females,
and 904 (61.16%) overall who received a secondary diagnosis
of MDE, respectively.
Comorbidities of Primary Anxiety Disorders
As shown in Multimedia Appendix 2, each anxiety disorder
was comorbid with other anxiety disorders. GAD was the most
comorbid anxiety disorder with other anxiety disorders ranging
from 58.0% (327/564) with specific phobia to 62.31%
(921/1478) with PD/A. SAD was the second most comorbid
anxiety disorder with other anxiety disorders ranging from
39.5% (183/463) with OCD to 65.1% (334/513) with
agoraphobia without panic disorder. The third was specific
phobia with a range from 31.6% (162/513) with agoraphobia
without panic disorder to 44.25% (654/1478) with PD/A. The
fourth was PD/A with a range from 28.25% (378/1338) with
SAD to 41.0% (231/564) with specific phobia. The fifth was
PTSD with a range from 20.7% (96/463) with OCD to 31.39%
(464/1478) with PD/A. The sixth was OCD with a range from
8.95% (184/2056) with GAD to 34.9% (176/504) with PTSD.
The seventh was agoraphobia without panic disorder with a
range from 13.8% (64/463) with OCD to 28.10% (376/1338)
with SAD.
Comorbidities of Depression, Anxiety Disorders,
Insomnia/Hypersomnia, and Drug and Alcohol Abuse
We first note that there were 858 males and 1761 females who
received a primary diagnosis of MDE—a 2 to 1 female to male
ratio. We also note the difference in comorbidity between males
and females who have been diagnosed with MDE and one of
the anxiety disorders. In all cases, except for OCD, the
comorbidities of MDE with PD/A, agoraphobia without panic
disorder, specific phobia, PTSD, GAD, and SAD among females
are greater than the comorbidity among males. In addition, about
65.50% (1735/2649) of those diagnosed with MDE suffer from
insomnia, whereas about 19.29% (511/2649) suffer from
hypersomnia, with females reporting symptoms of insomnia
and hypersomnia in greater numbers. Also, 21.10% (559/2649)
of those diagnosed with MDE report alcohol abuse with males
reporting alcohol use in greater numbers.
On average, we found 58.38% of those receiving a primary
diagnosis of one of the anxiety disorders also received a
secondary diagnosis of MDE. Conversely, on average, we found
approximately 35% of those who received a primary diagnosis
of MDE also received a secondary diagnosis of one or more
anxiety disorders. The lowest comorbidity was between MDE
and agoraphobia without panic disorder at about 17.93%
(475/2649), whereas the highest comorbidity was between MDE
and GAD at about 59.61% (1579/2649). The remaining anxiety
disorders in order of frequency magnitude were OCD
(710/26.80%), PD/A (712/2649, 26.88%), specific phobia
(803/2649, 30.31%), PTSD (883/2649, 33.33%), and SAD
(1336/2649, 50.43%).
Results show the presence of the following substance
dependency in participants who received a primary diagnosis
of MDE: cannabis (202/2649, 7.63%), stimulant (114/2649,
4.3%), opioid (71/2649, 2.68%), sedative (252/2649, 9.51%),
and alcohol (559/2649, 21.10%). Most significant was the
difference between depressed males and females in alcohol
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dependence (25.76% (221/858) for males vs 19.19% (338/1761)
for females).
The highest percentage of substance dependency present in all
anxiety disorders diagnosed by e-PASS was found for males
with GAD and alcohol dependence at 24.06% (141/586), for
females with specific phobia and alcohol dependence at 15.10%
(61/404), and for both males and females with GAD and alcohol
dependence at 17.41% (358/2056).
Results indicate insomnia was present in all disorders ranging
from 41.25% to 83.67% for the combined male/female samples.
For males, the co-occurrence of insomnia was found highest
with somatization disorder at 100% and lowest with opioid
dependency and OCD at 33.33% and 33.71%, respectively. For
females, the co-occurrence of insomnia was found highest with
somatization disorder at 80.0% (32/40) and lowest with alcohol
dependency at 42.1% (40/95).
Comorbidities of Eating Disorders With Anxiety and
Major Depressive Disorders
There were a total of 14 participants (3 males and 11 females)
diagnosed with anorexia nervosa, whereas 505 participants (26
males and 479 females) diagnosed with bulimia nervosa. Results
showed that 71.43% (0% males vs 90.91% females) and 71.68%
(80.77% males vs 71.19% females) of those receiving a primary
diagnosis of anorexia nervosa and bulimia nervosa, respectively,
also received a secondary diagnosis of MDE. The
co-occurrences of primary diagnosis of anorexia nervosa or
bulimia nervosa with the presence of a secondary diagnosis of
1 of 7 anxiety disorders for males, females, and the total sample
are extracted from Multimedia Appendix 2 and are shown in
Table 2.
Table 2. Comorbidities of anxiety disorders, MDE in anorexia nervosa and bulimia nervosa groups.
Bulimia nervosa, n (%)Anorexia nervosa, n (%)Anxiety disorders
Total (N=505)Female (n=479)Male (n=26)Total (N=14)Female (n=11)Male (n=3)
183 (36.2)171 (35.7)12 (46.2)6 (42.9)5 (45.5)1 (33.3)OCD
252 (49.9)239 (49.9)13 (50.0)8 (57.1)7 (63.6)1 (33.3)SAD
263 (52.1)248 (51.8)15 (57.7)9 (64.3)8 (72.7)1 (33.3)GAD
131 (25.9)126 (26.3)5 (19.2)3 (21.4)3 (27.3)0 (0.0)PD/A
167 (33.1)160 (33.4)7 (26.9)3 (21.4)2 (18.2)1 (33.3)PTSD
136 (26.9)127 (26.5)9 (34.6)4 (28.6)4 (36.4)0 (0.0)SP
71 (14.1)64 (13.4)7 (26.9)2 (14.3)1 (9.1)1 (33.3)AwoPD
As shown in Table 2, the comorbidity rate of anorexia nervosa
with any of the 7 anxiety disorders was highest for females
diagnosed with GAD at 72.7% and lowest for females diagnosed
with agoraphobia without panic disorder at 9.1%. Similarly, the
comorbidity rate of bulimia nervosa with any of the 7 anxiety
disorders was highest for females diagnosed with GAD at 51.8%
and lowest for females diagnosed with PD/A at 26.3%.
It should be noted that the rate of comorbidity depends on the
reference group. For example, as shown in Multimedia Appendix
2, the rate of co-occurrence of MDE in the bulimia nervosa
group was 80.8% (21/26) for males, 71.2% (341/479) for
females, and 71.7% (362/505) for both. However, the rate of
co-occurrence of bulimia nervosa in the MDE group was found
to be 4.6% (39/858) for males, 14.82% (261/1761) for females,
and 11.33% (300/2649) for both, and the rate of co-occurrence
of anorexia nervosa in the MDE group was found to be 0% for
males, 1% for females, and 1% for both.
Relationships Between Comorbidities of Anxiety and
Depressive Disorders and Psychosocial Variables
The data contained 6 anxiety disorders with the following
primary diagnoses frequencies: GAD (n=2056), PD/A (n=1478),
SAD (n=1338), specific phobia (n=564), PTSD (n=504), and
OCD (n=463). The data also contained 2649 participants who
received a primary diagnosis of MDE. Cross-tabulation of these
7 disorders resulted in cells with fewer than 5 participants. To
maintain a cell count of 5 or greater, specific phobia, PTSD,
and OCD were removed from further analyses. For the next
several hierarchical loglinear analyses, MDE, GAD, PD/A, and
SAD were used with each of the following variables: suicidal
ideation, social support, and quality of life. In addition, age was
split into young (those between 18 and 35 years old) and older
(those over 35 years old). Sex of participants was also split into
males and females.
Anxiety, Depression, and Suicidal Ideation
Three anxiety disorders (PD/A, SAD, GAD) and MDE with
suicidal ideation were entered into a hierarchical loglinear
regression. The 5-way loglinear analyses resulted in a model
with a non-significant likelihood ratio (χ210=9.6, P=.476) that
retained 3-way effects (χ216=97.7, P<.001). Results of the
backward elimination showed 2 significant triads that contained
suicidal ideation: PD/A*SAD*suicidal ideation and
PD/A*MDE*suicidal ideation. Two new hierarchical loglinear
models were constructed. The first model was based on PD/A,
SAD, suicidal ideation, age, and sex that resulted in a
non-significant likelihood ratio (χ210=12.7, P=.240) that retained
3-way effects (χ216=81.5, P<.001). The second model was based
on PD/A, MDE, suicidal ideation, age, and sex which resulted
in a non-significant likelihood ratio (χ210=6.5, P=.772) that
retained 3-way effects (χ216=34.8, P=.004). Consequently, a
new model with PD/A, SAD, MDE, suicidal ideation, age, and
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sex with only 3-way effects resulted in a non-significant
likelihood ratio (χ232=22.4, P=.90). Backward elimination
resulted in 2 significant triads that included suicidal ideation,
MDE-PD/A comorbidity dyad and PD/A-SAD comorbidity
dyad, as shown in Table 3. A 2x2 cross-tabulation for those
who reported no suicidal ideation and for those who reported
suicidal ideation was performed separately for the MDE-PD/A
comorbidity dyad and for the PD/A-SAD comorbidity dyad.
Table 3. Values and significance of chi square test for 3-way interactional terms for MDE, PD/A, SAD, sex, and age with suicidal ideation.
Pχ2(df=1)3-way interaction
.00013.7MDE*PD/A*SAD
.0067.6MDE*PD/A*suicidal ideation
.0048.3MDE*SAD*Sex
.00014.3PD/A*SAD*Suicidal ideation
.00022.7PD*SAD*Age
.0146.0Suicidal Ideation*Sex*Age
MDE-PD/A Comorbidity Dyad
For the non-suicidal ideation group, there was a significant
association between MDE and whether or not PD/A was
endorsed (χ21=11.1, P=.001). The odds for the non-suicidal
ideation group endorsing both MDE and PD/A were 1.18 times
higher than if they had endorsed MDE only. For the suicidal
ideation group, there was a significant association between MDE
and whether or not PD/A was endorsed (χ21=21.0, P<.001). This
was based on the finding that the odds of the suicidal ideation
group endorsing both MDE and PD/A were 1.84 times higher
than if they had endorsed MDE only. The frequencies of all
combinations of PD/A, MDE, sex, and age of those who reported
suicidal ideation are shown in Table 4, and a graph illustrating
the effect of sex and age on suicidal ideation when there is PD/A
and MDE comorbidity is shown in Figure 2.
Table 4. Frequencies (%) of those endorsing suicidal ideation by PD/A*MDE*Sex*Age.
Suicidal ideation, n/N (%)AgeSexMDEPD/A
309/547 (56.5)Y (≤35)MYesYes
266/449 (59.2)O (>35)MYesYes
1075/1757 (61.18)YFYesYes
416/809 (51.4)OFYesYes
15/183 (8.2)YMNoYes
12/170 (7.1)OMNoYes
40/550 (7.3)YFNoYes
18/314 (5.7)OFNoYes
455/908 (50.1)YMYesNo
416/883 (47.1)OMYesNo
1194/2419 (49.36)YFYesNo
676/1547 (43.70)OFYesNo
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Figure 2. Sex by age for those who endorsed suicidal ideation (% frequency) and endorsed PD/A and MDE.
PD/A-SAD Comorbidity Dyad
For the non-suicidal ideation group, there was a significant
association between PD/A and whether or not SAD was
endorsed (χ21=34.6, P<.001). The odds of the non-suicidal
ideation group endorsing both PD/A and SAD were 1.32 times
higher than if they had endorsed PD/A only. For the suicidal
ideation group, there was a significant association between
PD/A and whether or not SAD was endorsed by this group
(χ21=140.4, P<.001). The odds of the suicidal ideation group
endorsing both PD/A and SAD were 2.07 times higher than if
they had endorsed PD/A only. The frequencies of all
combinations of PD/A, SAD, sex, and age of those who reported
suicidal ideation are shown in Table 5, and a graph of the effect
of age and sex on suicidal ideation in the presence of a PD/A
and SAD comorbidity is shown in Figure 3.
Table 5. Frequencies (%) of those endorsing suicidal ideation by PD/A*SAD*Sex*Age.
Suicidal ideation, n/N (%)AgeSexSADPD/A
244/479 (50.9)Y (≤35)Myesyes
197/392 (50.28)O (>35)Myesyes
842/1496 (56.3)YFyesyes
314/689 (45.6)OFyesyes
80/251 (31.9)YMnoyes
81/227 (35.7)OMnoyes
273/811 (33.7)YFnoyes
120/434 (27.6)OFnoyes
303/776 (39)YMyesno
247/633 (39)OMyesno
804/2021 (39.78)YFyesno
361/1049 (34.41)OFyesno
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Figure 3. Sex by age for those who endorsed suicidal ideation (% frequency) and endorsed PD/A and SAD.
Anxiety, Depression, and Social Support
Three anxiety disorders (PD/A, SAD, GAD) and MDE with
social support were entered into a hierarchical loglinear
regression. The 5-way loglinear resulted in a model, with a
non-significant likelihood ratio (χ210=7.1, P=.72), which retained
3-way effects (χ216=86.5, P<.001). Results of the backward
elimination showed 1 significant triad that contained social
support, PD/A*GAD*social support (χ21=4.3, P=.038). The
remaining 4 significant triads were the 3-way interactions of
MDE*GAD*PD/A, MDE*GAD*SAD, GAD*PD/A*SAD, and
MDE*PD/A*SAD that did not include social support. A
hierarchical loglinear model was constructed using PD/A, GAD,
and social support with sex and age. The resulting model had
a non-significant likelihood ratio (χ210=2.2, P=.994) that retained
3-way effects (χ216=40.4, P=.001). A new model with only
3-way effects resulted in a non-significant likelihood ratio
(χ216=17.7, P=.35). Backward elimination resulted in one
significant triad that included social support and GAD-PD/A
comorbidity dyad, as shown in Table 6.
Table 6. Values and significance of chi square test for 3-way interactional terms for GAD, PD/A, sex, and age with social support.
Pχ2(df=1)3-way interaction
.0029.6GAD*PD/A*Social Support
.00019.6GAD*Sex*Age
.00042.5PD*Age
.00014.9Social Support*Sex
A 2x2 cross-tabulation for those who reported inadequate social
support and for those who reported adequate social support was
performed separately for the GAD-PD/A comorbidity dyad. For
those who reported inadequate social support, there was a
significant association between GAD and whether or not PD/A
was endorsed (χ21=119.12, P<.001). This was based on the
finding that the odds of inadequate social support group
endorsing both GAD and PD/A were 1.84 times higher than if
they had endorsed GAD only. For those who reported adequate
social support, there was a significant association between GAD
and whether or not PD/A was endorsed (χ21=40.31, P<.001).
The odds of the adequate social support group endorsing both
GAD and PD/A were 1.42 times higher than if they had endorsed
GAD only. Table 7 shows the frequencies of all combinations
of PD/A, GAD, sex, and age of those who endorsed adequate
social support.
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Table 7. Frequencies (%) of those endorsing social support by PD/A*GAD*Sex*Age.
Social support, n/N (%)AgeSexGADPD/A
189/507 (37.3)Y (≤35)MYesYes
166/435 (38.2)O (>35)MYesYes
671/1744 (38.47)YFYesYes
304/793 (38.3)OFYesYes
116/223 (52.0)YMNoYes
97/184 (52.7)OMNoYes
294/563 (52.2)YFNoYes
193/330 (58.5)OFNoYes
301/781 (38.5)YMYesNo
306/787 (38.9)OMYesNo
1032/2362 (43.69)YFYesNo
639/1421 (44.97)OFYesNo
Anxiety, Depression, and Quality of Life
Three anxiety disorders (PD/A, SAD, GAD) and MDE with
quality of life were entered into a hierarchical loglinear
regression. The 5-way loglinear resulted in a model, with a
non-significant likelihood ratio (χ210=11.1, P=.35) that retained
3-way effects (χ216=92.6, P<.001). Results of the backward
elimination showed 1 significant triad that contained quality of
life, PD/A*SAD*quality of life (χ21=4.6, P=.031). The
remaining 3 significant triads were the 3-way interactions of
MDE*PD/A*SAD, MDE*GAD*SAD, and MDE*GAD*PD/A
that did not include quality of life. A hierarchical loglinear
model was constructed using PD/A, SAD, and quality of life
with sex and age. The resulting model had a non-significant
likelihood ratio (χ210=7.7, P=.66) that retained 3-way effects
(χ216=56.0, P<.001). A new model with only 3-way effects
resulted in a non-significant likelihood ratio (χ213=14.1, P=.37).
Backward elimination resulted in one significant triad that
included quality of life and PD/A-SAD comorbidity dyad. The
rest of the 5 significant triads did not include any comorbidity
dyad with the quality of life term, as shown in Table 8.
Table 8. Values and significance of chi square test for 3-way interactional terms for SAD, PD/A, sex, and age with quality of life.
Pχ2(df=1)3-way interaction
.00016.4PD*Quality of Life*SAD
.0424.1PD*Quality of Life*Sex
.00018.0PD*SAD*Age
.0404.2PD*Sex*Age
.0205.4SAD*Sex
A 2x2 cross-tabulation for those who reported poor quality of
life and for those who reported good quality of life was
performed separately for PD/A-SAD comorbidity dyad. For
those who reported poor quality of life, there was a significant
association between PD/A and whether or not SAD was
endorsed (χ21=130.1, P<.001). This was based on the finding
that the odds of poor quality of life group endorsing both PD/A
and SAD were 1.87 times higher than if they had endorsed PD/A
only. For those who reported good quality of life, there was a
significant association between PD/A and whether or not SAD
was endorsed by this group (χ21=34.3, P<.001). The odds of the
good quality of life group endorsing both PD/A and SAD were
1.35 times higher than if they had endorsed PD/A only. The
frequencies of all combinations of PD/A, SAD, sex, and age of
those who endorsed good quality of life are shown in Table 9.
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Table 9. Frequencies (%) of those endorsing quality of life by PD/A, SAD, sex, and age.
Quality of life, n/N (%)AgeSexSADPD/A
188/479 (39.2)Y (≤35)MYesYes
145/392 (37.0)O (>35)MYesYes
567/1496 (37.90)YFYesYes
270/689 (39.2)OFYesYes
147/251 (58.6)YMNoYes
113/227 (54.4)OMNoYes
503/811 (62.0)YFNoYes
253/434 (58.3)OFNoYes
339/776 (43.7)YMYesNo
386/663 (45.2)OMYesNo
1011/2021 (50.02)YFYesNo
519/1049 (49.48)OFYesNo
Discussion
Principal Findings
A frequency matrix of the co-occurrence of 21 psychological
disorders based on primary and secondary diagnoses of 12,665
individuals who were assessed using the e-PASS online
diagnostic system was constructed. To the best of our
knowledge, such a matrix for this many psychological disorders
has not been presented before for traditional in-clinic diagnosis
or for any online diagnostic tools. As such, comparisons with
existing literature should be viewed with caution. We present
this matrix to serve as a preliminary and potentially useful
reference for future works in the area of online assessment and
diagnosis.
Given the high number of disorders in the matrix and limited
discussion space, we will focus on a few disorders that are of
most interest and/or have been studied before in in-clinic
samples.
Depression, Anxiety Disorders, Insomnia/Hypersomnia,
and Drug and Alcohol Abuse
One area that has been studied extensively is the comorbidity
of MDE and the various anxiety disorders, and alcohol abuse.
We found the number of females receiving a primary diagnosis
of MDE was twice the number of males receiving a primary
diagnosis of MDE. This ratio of about 2:1 females to males is
consistent with in-clinic samples and face-to-face diagnostic
tools. We also found the comorbidities of MDE with all anxiety
disorders, except for OCD, among females to be greater than
the same comorbidities among males. In addition, the majority
(2 in 3) of those diagnosed with MDE reported insomnia,
whereas 1 in 5 reported hypersomnia, with greater numbers of
females than males reporting symptoms of insomnia and
hypersomnia. Moreover, 1 in 5 of those diagnosed with MDE
reported alcohol abuse with greater numbers of males than
females reporting alcohol abuse.
On average, we found approximately 1 in 3 of those who
received a primary diagnosis of MDE also received a secondary
diagnosis of one or more anxiety disorders. The lowest
comorbidity was found between MDE and agoraphobia without
panic disorder whereas the highest comorbidity was between
MDE and GAD. These results are consisted with findings based
on in-clinic samples [15,21,24,25,66]. Our findings are also
consistent with Fava et al [24] who found that 46% of MDD
patients were significantly more likely to report symptoms
associated with GAD, OCD, PTSD, agoraphobia without panic
disorder, and PD/A than individuals without comorbid anxiety.
On the higher end, Almeida-Filho et al [23] found 74% of a
depressed Brazilian sample reported symptoms of anxiety
disorders, which is much higher than our results of 35%. This
discrepancy is possibly due to the fact that they used reported
symptoms of anxiety disorders, whereas this study used
adherence to the DSM-IV-TR diagnostic criteria. On the other
hand, our result that almost 2 in 3 of those receiving a primary
diagnosis of one of the anxiety disorders was also receiving a
secondary diagnosis of MDE is consistent with Almeida-Filho
et al’s [23] results that 61% of those with anxiety disorders were
depressed.
We also found high rates of comorbidities among anxiety
disorders with GAD being the most comorbid anxiety disorder
with other anxiety disorders followed by SAD, specific phobia,
PD/A, PTSD, OCD, and agoraphobia without panic disorder.
These results are consistent with previous research findings that
found anxiety disorders to have high comorbidities with each
other and that questioned the discriminant validity of some
anxiety diagnoses such as GAD [5,8-13]. This consistency may
suggest that there are no differences between online and in-clinic
assessment systems and online and in-clinic populations.
The comorbidities between MDE and various substance
dependency (ranging between 3% to 21%) found in this study
are much lower than the 42% of mood disordered patients who
had substance use disorders as reported by McGovern et al [37].
Again, this discrepancy may be due to this study’s strict
adherence to the diagnostic criteria.
The highest comorbidity of substance dependency present in
all anxiety disorders was found for males who received a
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primary diagnosis of GAD and a secondary diagnosis of alcohol
dependence at 24.06%, and for females who received a primary
diagnosis of specific phobia and a secondary diagnosis of
alcohol dependence at 15.10%. McGovern et al [37], without
examining males and females separately, found substance use
disorders present in 27% of patients diagnosed with anxiety
disorders, which is, again, slightly greater than results of this
study of about 17% for the combined male and female samples.
Almeida-Filho et al [23] found 20% of cases of alcoholism
co-occurring with anxiety disorders and MDD diagnoses.
This study also found insomnia to be present in all disorders
ranging from 41.25% to 83.67% for the combined male/female
samples across all disorders. This association between insomnia
and psychological disorders is consistent with the literature. For
example, the presence of sleep problems has been consistently
found in patients with anxiety and mood disorders [5,26-30].
Eating Disorders, Anxiety Disorders, and Major
Depression
The interpretation of the comorbidities of anorexia nervosa with
other disorders should be viewed with caution because of the
small number of participants who were diagnosed with anorexia
nervosa. Overall, our results are consistent with the previously
found rates of anorexia nervosa and bulimia nervosa
comorbidities with MDE and anxiety disorders. Specifically,
we found 71.43% and 71.68% of those receiving a primary
diagnosis of anorexia nervosa and bulimia nervosa, respectively,
also received a secondary diagnosis of MDE. The comorbidity
of anorexia nervosa and MDE found in this study is within the
range of 50%-71% reported by previous studies [33,34,40-42].
However, the result for the comorbidity of bulimia nervosa and
MDE found in this study is slightly greater than the range of
50%-65% reported by previous investigations [33,34,40,41].
The rates of co-occurrence of bulimia nervosa and anorexia
nervosa in the MDE group found in this study are consistent
with the estimated lifetime prevalence of anorexia nervosa in
MDD (1%-7%) and of bulimia nervosa in MDD (9%-21%)
reported by Carter et al [43] and Fava et al [44]. It is expected
that a larger proportion of bulimia nervosa individuals
experience symptoms of depression while a much smaller
percentage of depressed individuals experience symptoms of
bulimia nervosa.
While the choice of the reference group is very important in
establishing comorbidity rates, it varies in importance. For
example, while defining the reference group in the case of MDE
or anxiety disorders and bulimia nervosa or anorexia nervosa
is important, it is less so when defining the reference group for
MDE and GAD. As shown in Multimedia Appendix 2, the
co-occurrence of MDE in the GAD group is 66.83% whereas
the co-occurrence of GAD in the MDE group is 59.61% for
combined male and female sample.
For the most part, results of this study are consistent with
previous findings. However, results do not fall within the range
found in previous studies on three occasions. The comorbidity
rate for anorexia nervosa with GAD (64%) found by this study
is outside the range of 24%-49% reported by Godart et al
[47,54]. Similarly the comorbidity rate for anorexia nervosa
with PTSD (21%) is outside the range of 2%-7% given by
Godart et al [47]. In both cases, the results of this study are
based on very few participants with anorexia nervosa and
therefore should be interpreted with caution. Finally, the
comorbidity rate for bulimia nervosa with MDE (72%) is slightly
outside the range of 61%-65% reported by Jordan et al [34] and
Casper [33].
This study also examined the interactional relationships between
GAD, SAD, PD/A, MDE, sex, and age and three variables:
suicidal ideation, social support, and quality of life using a series
of hierarchical loglinear analyses. In each case, 3-way interaction
effects were found. For suicidal ideation, the odds of endorsing
having suicidal ideation was greater for those diagnosed with
depression and PD/A than depression only, and for those
diagnosed with PD/A and SAD than PD/A only. These results
suggest that comorbidity, even for two disorders, increases the
risk of having suicidal thoughts, as indicated by previous
research [3-5]. We also found a significant interactional effect
for sex by age. The frequency of younger females (18-35 years
old) diagnosed with MDE and PD/A or PD/A and SAD
endorsing suicidal ideation was about 10% greater than older
females (over 35 years old) and about 5% greater than their
counterpart younger or older males. These results suggest that
younger females who have these comorbidity dyads are at
greater risk of having suicidal ideation.
The results of this study found the GAD and PD/A dyad to be
the only one to have a significant relationship with social
support. The odds for reporting having inadequate social support
was greater for those diagnosed with GAD and PD/A than GAD
only. There are not many studies that examined the relationship
between comorbidity and social support, but one recent study
reported a negative relationship between comorbidity and social
support [5]. We should note here that this study found no
significant interactional effect between GAD and PD/A
comorbidity dyad and sex, age, and social support. These results
suggest that sex and age have little effect on the relationship
between this dyadic comorbidity and social support.
Finally, the results suggested that the PD/A and SAD dyad was
the only dyad to have a significant relationship with quality of
life. The odds for reporting having a poor quality of life was
greater for those diagnosed with PD/A and SAD than PD/A
only. Again, only one study reported a negative relationship
between comorbidity and quality of life [5]. Also, as was the
case with social support, we found no significant interactional
effect between the PD/A-SAD comorbidity dyad and sex, age,
and quality of life. These results suggest that sex and age have
no effect on the relationship between this dyadic comorbidity
and quality of life.
Transdiagnostic Approaches
There is growing support for using transdiagnostic approaches
for the assessment and treatment of psychological disorders.
AL-Asadi et al [5] using dimensional scales found overlapping
dimensions underlying the various psychological disorders.
Moses and Barlow [67] and Barlow et al [68] concluded that at
a minimum, a diagnostic specific approach and transdiagnostic
approaches to treatments are equally effective. AL-Asadi et al
[69] found significant reduction in the severity of symptoms of
J Med Internet Res 2015 | vol. 17 | iss. 3 | e55 | p.12http://www.jmir.org/2015/3/e55/
(page number not for citation purposes)
AL-Asadi et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
depression as a result of participants receiving anxiety-specific
treatment and supported the efficacy of online therapy to provide
transdiagnostic treatment. McEvoy et al’s [70] review of the
literature concluded that transdiagnostic treatments were
associated with improvements in comorbidity disorders and
with high client satisfaction, therapeutic alliance, group
cohesion, and positive treatment expectations. McManus et al
[71] pointed out the potential of transdiagnostic approaches in
addressing multiple comorbid anxiety disorders. Wade et al [72]
found support for using transdiagnostic approaches to
understanding eating disorders. Results of this study provide
further support for the use of transdiagnostic approaches to the
assessment and treatment of psychological disorders.
Limitations
One of the major limitations of this study is the lack of a control
group. The online system does not require the inclusion of a
control group and consequently any conclusion must be taken
as preliminary. Another limitation is the lack of research on the
sensitivity and the psychometric properties of the e-PASS
system. There is only one unpublished study that found the
e-PASS system to have high test-retest reliability and adequate
convergent validity (Nguyen, unpublished PhD thesis, 2013).
Unfortunately, even this one study has used a small sample size
and found disagreement between e-PASS and structured clinical
interviews when it came to the level of severity required for a
clinical diagnosis. More validation studies with larger samples
and using the newly released DSM-5 criteria are required before
definitive conclusions can be made. The last limitation is
inherent to all self-report instruments such as e-PASS. The
exclusive reliance of e-PASS on automated online self-report
measures brings into question the extent to which diagnosing
individuals is reliable. Concerns have been raised regarding the
reliability of online diagnostic tools [73].
Conclusions
In summary, overlap between psychological disorders for our
online sample using the online assessment tool, e-PASS, was
confirmed and was found to be similar to in-clinic samples using
face-to-face assessment tools. Overall, there did not appear to
be much difference in the rates of comorbidities of psychological
disorders between in-clinic samples using face-to-face
assessment and diagnostic tools and our online sample using
the online assessment and diagnostic tool, e-PASS. The results
of this study showed that the comorbidity rates for the online
sample using e-PASS commonly fell within the range found
for in-clinic samples using in-clinic assessment tools. The
observation that e-PASS and face-to-face assessment tools
generally yielded the same result may provide further evidence
to the validity and the utility of the Anxiety Online Platform
and the e-PASS assessment tool. Findings of this study
supported the use of transdiagnostic approaches in the
assessment and treatment of psychological disorders. Moreover,
dyadic disorder comorbidities of some anxiety disorders and
MDE were found to increase the odds for having suicidal
ideation, inadequate social support, and poorer quality of life
than a diagnosis of only one of the two making up the dyadic
disorder.
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